John G Ullman & Associates Inc. Has $382,000 Stock Position in Novartis AG $NVS

John G Ullman & Associates Inc. cut its position in Novartis AG (NYSE:NVS) by 97.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,980 shares of the company’s stock after selling 134,427 shares during the period. John G Ullman & Associates Inc.’s holdings in Novartis were worth $382,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Lockheed Martin Investment Management Co. lifted its stake in shares of Novartis by 15.6% in the third quarter. Lockheed Martin Investment Management Co. now owns 85,200 shares of the company’s stock valued at $10,926,000 after buying an additional 11,500 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Novartis by 5.5% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 132,536 shares of the company’s stock worth $17,001,000 after acquiring an additional 6,924 shares during the last quarter. Keybank National Association OH lifted its position in Novartis by 13.2% in the 2nd quarter. Keybank National Association OH now owns 49,377 shares of the company’s stock valued at $5,975,000 after acquiring an additional 5,742 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in Novartis by 27.7% during the 3rd quarter. Geneos Wealth Management Inc. now owns 64,760 shares of the company’s stock valued at $8,305,000 after purchasing an additional 14,032 shares during the last quarter. Finally, Dynasty Wealth Management LLC bought a new stake in Novartis during the 3rd quarter worth approximately $1,491,000. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Trading Up 0.6%

NYSE NVS opened at $153.80 on Friday. The business’s fifty day moving average is $140.19 and its 200-day moving average is $130.52. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.88 and a quick ratio of 0.68. The stock has a market capitalization of $324.89 billion, a price-to-earnings ratio of 21.48, a PEG ratio of 2.00 and a beta of 0.50. Novartis AG has a one year low of $97.71 and a one year high of $154.95.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.04. Novartis had a net margin of 25.65% and a return on equity of 41.70%. The company had revenue of $524.00 million during the quarter, compared to analyst estimates of $13.85 billion. During the same quarter in the prior year, the business earned $1.98 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Equities research analysts predict that Novartis AG will post 8.45 EPS for the current year.

Novartis Dividend Announcement

The business also recently declared an annual dividend, which will be paid on Monday, March 16th. Stockholders of record on Wednesday, March 11th will be paid a dividend of $4.773 per share. The ex-dividend date is Wednesday, March 11th. This represents a dividend yield of 312.0%. Novartis’s dividend payout ratio (DPR) is presently 36.31%.

Key Headlines Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Q4 EPS beat and margin improvement — Novartis reported EPS above estimates and expanded core margins, supporting profitability expectations. MarketBeat Earnings Summary
• Positive Sentiment: Pipeline progress and upcoming readouts — management highlighted multiple late-stage milestones (e.g., remibrutinib filing steps, Pluvicto and Scemblix advances) that support medium-term growth expectations. GlobeNewswire Q4 Release
• Positive Sentiment: Dividend and capital returns — the company announced an annual dividend increase and continues shareholder-friendly actions (buybacks), which supports investor sentiment. GlobeNewswire Dividend & Results
• Neutral Sentiment: Analyst stance largely supportive — several firms (Citi, BofA) maintained Buy ratings and see EPS upside despite near-term headwinds, helping stabilize sentiment. TipRanks Analyst Notes
• Neutral Sentiment: Deep dives and investor materials available — full earnings call transcripts and slide decks were published for investors who want details on segment performance and assumptions. Earnings Call Transcript (MSN)
• Negative Sentiment: Revenue miss and generics pressure — Q4 sales missed estimates as U.S. generic entrants eroded Entresto and Promacta sales, changing near-term growth mix. Benzinga on Generics/Pipeline
• Negative Sentiment: Cautious 2026 guidance — management expects a low single-digit decline in core operating profit for 2026 due to generic competition, which caps near-term earnings momentum. Reuters Guidance Report
• Negative Sentiment: Patent expiries and ESG/sustainability risks — analysts flag a major upcoming patent cliff and new ESG disclosures that could weigh on reputation, pricing power and financing over time. TipRanks ESG Risk Note

Analyst Upgrades and Downgrades

NVS has been the topic of a number of recent research reports. Cfra set a $126.00 target price on Novartis and gave the company a “hold” rating in a report on Wednesday, October 29th. Cfra Research upgraded Novartis to a “hold” rating in a research note on Wednesday, October 29th. Morgan Stanley reaffirmed an “overweight” rating on shares of Novartis in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a report on Monday, December 29th. Finally, HC Wainwright lowered shares of Novartis to a “neutral” rating in a research report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Novartis currently has a consensus rating of “Hold” and an average price target of $119.75.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.